Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Pediatrics

Beyond the Newborn Period: Long-Term Monitoring and Growth

At a Glance

Lifelong monitoring is essential for children with Tyrosinemia Type 1 (HT1). Even with effective treatment, patients require regular liver imaging and AFP blood tests every 6-12 months to screen for liver cancer. Neuropsychological testing is also vital to identify and support learning challenges.

While the modern treatment of Tyrosinemia Type 1 (HT1) has significantly improved the quality and length of life, it is a journey that requires lifelong vigilance. Managing HT1 is not just about daily medication and diet; it is also about staying ahead of potential complications through regular, proactive screening [1][2].

Protecting the Liver: The Need for Surveillance

One of the most important things for parents to understand is that even with excellent treatment, the risk of hepatocellular carcinoma (HCC)—a type of liver cancer—does not disappear completely [3][2].

Even when toxins like succinylacetone are controlled, some molecular changes in the liver can persist. This is especially true for children who started treatment later in infancy, but it remains a factor for all patients [2][3]. To catch any issues early, your team will follow a strict surveillance schedule:

  • Alpha-fetoprotein (AFP): This is a protein measured through a blood test. High or rising levels can be an early warning sign of liver stress or tumor growth [4].
  • Liver Imaging: Blood tests are not enough. Some tumors can develop even when AFP levels are normal [5]. Doctors use ultrasounds, MRIs, or CT scans to get a clear picture of the liver and check for any unusual nodules or growths [6][7].

The frequency of these tests depends on your child’s age and clinical history, but they are typically performed every 6 to 12 months for life [8].

Supporting the Developing Mind

As children with HT1 grow, we have learned that the condition can affect how the brain processes information. Even with nitisinone and a low-protein diet, some children may experience neurocognitive or behavioral challenges [9][10].

Common Areas of Concern

Researchers have observed that children with HT1 may face difficulties in the following areas:

  • Executive Functioning: Challenges with planning, organizing, and staying focused [10].
  • Processing Speed: Taking a bit longer to process information or complete tasks [9].
  • Social Cognition: Difficulty navigating social interactions or understanding social cues [10].
  • Learning Disabilities: Issues with specific school subjects or attention-deficit/hyperactivity disorder (ADHD) symptoms [9].

The Importance of Comprehensive Screening

Standard IQ tests may not capture these specific challenges. It is recommended that children with HT1 receive neuropsychological assessments at key developmental milestones (such as before starting kindergarten and during the transition to middle school) [10]. Identifying these issues early allows for school accommodations and support strategies that help your child thrive academically [11].

Managing the “Scanxiety”

The requirement for lifelong testing can create a persistent sense of worry, often called “scanxiety.” It is helpful to remember:

  • Screening is a Safety Net: These tests are designed to find very small issues before they become big problems, when they are most treatable [12].
  • A Multi-Person Effort: You are part of a team that includes psychologists and social workers who are there to support your family’s emotional well-being, not just your child’s physical health [11][13].
  • Advocacy: By staying consistent with monitoring, you are providing your child with the best possible long-term outlook [2].
Area of Health Monitoring Method Goal
Liver AFP blood tests & Imaging (US/MRI) Early detection of nodules or HCC [6]
Kidneys Blood/Urine Chemistry Checking for Fanconi syndrome or mineral loss [2]
Brain Neuropsychological testing Identifying learning or attention needs [10]
Eyes Ophthalmologic exams Monitoring for corneal crystals (keratopathy) [14]

Common questions in this guide

Why does my child with HT1 still need liver screenings if their treatment is working?
Even with successful treatment and controlled toxin levels, the risk of developing liver cancer remains. Regular monitoring helps catch any cellular changes or tumor growth early when it is most treatable.
How often will my child need liver imaging for Tyrosinemia Type 1?
Liver imaging, such as ultrasounds, MRIs, or CT scans, is typically performed every 6 to 12 months for life. Your care team will determine the exact schedule based on your child's specific age and medical history.
Do normal alpha-fetoprotein (AFP) levels mean my child's liver is completely healthy?
Not necessarily. While normal AFP levels are a good sign, some liver tumors can still develop without causing AFP levels to rise. This is why regular imaging tests are always required alongside blood work.
How can Tyrosinemia Type 1 affect my child's learning and development?
HT1 can impact brain processing, leading to challenges with executive function, processing speed, and social cognition. Regular neuropsychological assessments can help identify these issues early so appropriate school accommodations can be made.
What is the best way to handle the anxiety of lifelong medical testing?
Experiencing 'scanxiety' before tests is common. It helps to view screenings as a proactive safety net designed to catch issues early. You can also lean on your child's care team, including social workers and psychologists, for emotional support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why does the risk of liver cancer persist even though my child's succinylacetone is undetectable?
  2. 2.What imaging method (ultrasound vs. MRI) do you recommend for our next liver screening, and how often will we do this?
  3. 3.Can we schedule a baseline neuropsychological evaluation before my child starts school?
  4. 4.If my child's AFP levels are normal, does that mean we can skip the imaging, or are both necessary?
  5. 5.Are there specific signs of 'executive function' issues I should be looking for as my child reaches preschool age?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.

    van Ginkel WG, Rodenburg IL, Harding CO, et al.

    Paediatric drugs 2019; (21(6)):413-426 doi:10.1007/s40272-019-00364-4.

    PMID: 31667718
  2. 2

    Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.

    Dweikat I, Qawasmi N, Najeeb A, Radwan M

    Metabolism open 2021; (9()):100083 doi:10.1016/j.metop.2021.100083.

    PMID: 33598652
  3. 3

    Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.

    Neuckermans J, Lequeue S, Claes P, et al.

    Genes 2023; (14(3)) doi:10.3390/genes14030693.

    PMID: 36980965
  4. 4

    Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.

    Vongsuvanh R, van der Poorten D, Iseli T, et al.

    PloS one 2016; (11(5)):e0155800 doi:10.1371/journal.pone.0155800.

    PMID: 27219517
  5. 5

    Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.

    Bhushan S, Noble C, Balouch F, et al.

    Pediatric transplantation 2022; (26(7)):e14334 doi:10.1111/petr.14334.

    PMID: 35698261
  6. 6

    Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation.

    Gao J, Song P

    Drug discoveries & therapeutics 2017; (11(3)):168-169 doi:10.5582/ddt.2017.01036.

    PMID: 28757516
  7. 7

    The Heterogeneity of Liver Cancer Metabolism.

    Salazar J, Le A

    Advances in experimental medicine and biology 2021; (1311()):127-136 doi:10.1007/978-3-030-65768-0_9.

    PMID: 34014539
  8. 8

    Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).

    Das AM

    The application of clinical genetics 2017; (10()):43-48 doi:10.2147/TACG.S113310.

    PMID: 28769581
  9. 9

    Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet.

    García MI, de la Parra A, Arias C, et al.

    Molecular genetics and metabolism reports 2017; (11()):12-16 doi:10.1016/j.ymgmr.2017.01.016.

    PMID: 28377889
  10. 10

    Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls.

    van Ginkel WG, Jahja R, Huijbregts SC, et al.

    Orphanet journal of rare diseases 2016; (11(1)):87 doi:10.1186/s13023-016-0472-5.

    PMID: 27356512
  11. 11

    Dietary Considerations in Tyrosinemia Type I.

    van Spronsen FJ, van Rijn M, Meyer U, Das AM

    Advances in experimental medicine and biology 2017; (959()):197-204 doi:10.1007/978-3-319-55780-9_18.

    PMID: 28755197
  12. 12

    Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US.

    Singal AG, Mittal S, Yerokun OA, et al.

    The American journal of medicine 2017; (130(9)):1099-1106.e1 doi:10.1016/j.amjmed.2017.01.021.

    PMID: 28213044
  13. 13

    Caregiver Quality of Life with Tyrosinemia Type 1.

    Campbell H, Singh RH, Hall E, Ali N

    Journal of genetic counseling 2018; (27(3)):723-731 doi:10.1007/s10897-017-0157-9.

    PMID: 29110168
  14. 14

    Nitisinone causes acquired tyrosinosis in alkaptonuria.

    Khedr M, Cooper MS, Hughes AT, et al.

    Journal of inherited metabolic disease 2020; (43(5)):1014-1023 doi:10.1002/jimd.12229.

    PMID: 32083330

This page provides educational information about long-term monitoring for Tyrosinemia Type 1. Always consult your child's metabolic specialist or care team for personalized screening and care recommendations.

Get notified when new evidence is published on Tyrosinemia type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.